Drug Profile


Alternative Names: MK-7965; PS-095760; SCH 727965; SCHOOL 727965

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacopeia
  • Developer Merck & Co; University of California at San Francisco
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase I Breast cancer; Haematological malignancies
  • No development reported Non-small cell lung cancer
  • Discontinued Leukaemia; Mantle-cell lymphoma

Most Recent Events

  • 27 Jan 2017 Merck terminates a phase III trial in Chronic lymphocytic leukaemia (Second-line therapy or greater) due to program prioritisation and some safety or efficacy issues in USA, Belgium, Italy, Poland, Czech Republic, Sweden, Finland, Hungary, Lithuania, Latvia, Estonia, Spain, Greece, Norway and Slovakia
  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2016 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater) in USA (IV) (NCT02684617)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top